[1]
|
Vaddepally, R.K., Kharel, P., Pandey, R., et al. (2020) Review of Indications of FDA-Approved Immune Checkpoint In-hibitors per NCCN Guidelines with the Level of Evidence. Cancers (Basel), 12, Article No. 738.
https://doi.org/10.3390/cancers12030738
|
[2]
|
Brahmer, J., Reckamp, K.L., Baas, P., et al. (2015) Nivolumab ver-sus Docetaxel in Advanced Squamous-Cell Non- Small-Cell Lung Cancer. The New England Journal of Medicine, 373, 123-135.
https://doi.org/10.1056/NEJMoa1504627
|
[3]
|
Rosenberg, J.E., Hoffman-Censits, J., Powles, T., et al. (2016) Atezolizumab in Patients with Locally Advanced and Metastatic Urothelial Carcinoma Who Have Progressed Following Treatment with Platinum-Based Chemotherapy: A Single-Arm, Multicentre, Phase 2 Trial. The Lancet, 387, 1909-1920. https://doi.org/10.1016/S0140-6736(16)00561-4
|
[4]
|
Hodi, F.S., O’Day, S.J., McDermott, D.F., et al. (2010) Im-proved Survival with Ipilimumab in Patients with Metastatic Melanoma. The New England Journal of Medicine, 363, 711-723. https://doi.org/10.1056/NEJMoa1003466
|
[5]
|
Martins, F., Sofiya, L., Sykiotis, G.P., et al. (2019) Ad-verse Effects of Immune-Checkpoint Inhibitors: Epidemiology, Management and Surveillance. Nature Reviews Clinical Oncology, 16, 563-580.
https://doi.org/10.1038/s41571-019-0218-0
|
[6]
|
Bagchi, S., Yuan, R. and Engleman, E.G. (2021) Immune Check-point Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annual Re-view of Pathology, 16, 223-249.
https://doi.org/10.1146/annurev-pathol-042020-042741
|
[7]
|
Fan, S., Ren, H., Zhao, L., et al. (2020) Neurological Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors: A Review of the Literature. Asia-Pacific Journal of Clinical Oncology, 16, 291-298.
https://doi.org/10.1111/ajco.13375
|
[8]
|
Bruna, J., Argyriou, A.A., Anastopoulou, G.G., et al. (2020) Incidence and Characteristics of Neurotoxicity in Immune Checkpoint Inhibitors with Focus on Neuromuscular Events: Experience be-yond the Clinical Trials. Journal of the Peripheral Nervous System, 25, 171-177. https://doi.org/10.1111/jns.12371
|
[9]
|
Buchbinder, E.I. and Desai, A. (2016) CTLA-4 and PD-1 Pathways: Simi-larities, Differences, and Implications of Their Inhibition. American Journal of Clinical Oncology, 39, 98-106. https://doi.org/10.1097/COC.0000000000000239
|
[10]
|
Chen, D.S. and Mellman, I. (2017) Elements of Cancer Immunity and the Cancer-Immune Set Point. Nature, 541, 321-330. https://doi.org/10.1038/nature21349
|
[11]
|
Boutros, C., Tarhini, A., Routier, E., et al. (2016) Safety Profiles of An-ti-CTLA-4 and Anti-PD-1 Antibodies Alone and in Combination. Nature Reviews Clinical Oncology, 13, 473-486. https://doi.org/10.1038/nrclinonc.2016.58
|
[12]
|
Michot, J.M., Bigenwald, C., Champiat, S., et al. (2016) Im-mune-Related Adverse Events with Immune Checkpoint Blockade: A Comprehensive Review. European Journal of Cancer, 54, 139-148.
https://doi.org/10.1016/j.ejca.2015.11.016
|
[13]
|
Mohn, N., Beutel, G., Gutzmer, R., et al. (2019) Neurological Im-mune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook. Journal of Clinical Medicine, 8, Article No. 1777. https://doi.org/10.3390/jcm8111777
|
[14]
|
Cuzzubbo, S., Javeri, F., Tissier, M., et al. (2017) Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Review of the Literature. European Journal of Cancer, 73, 1-8. https://doi.org/10.1016/j.ejca.2016.12.001
|
[15]
|
Astaras, C., de Micheli, R., Moura, B., et al. (2018) Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management. Current Neurology and Neuroscience Reports, 18, Article No. 3.
https://doi.org/10.1007/s11910-018-0810-1
|
[16]
|
Guidon, A.C., Burton, L.B., Chwalisz, B.K., et al. (2021) Con-sensus Disease Definitions for Neurologic Immune-Related Adverse Events of Immune Checkpoint Inhibitors. Journal for ImmunoTherapy of Cancer, 9, e002890.
https://doi.org/10.1136/jitc-2021-002890corr1
|
[17]
|
Schneider, B.J., Naidoo, J., Santomasso, B.D., et al. (2021) Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology, 39, 4073-4126. https://doi.org/10.1200/JCO.21.01440
|
[18]
|
Lima, G., Kahn, A., Sama, S., et al. (2019) Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab. Case Reports in Oncological Medicine, 2019, Article ID: 7183747. https://doi.org/10.1155/2019/7183747
|
[19]
|
Wesley, S.F., Haggiagi, A., Thakur, K.T., et al. (2021) Neurological Immunotoxicity from Cancer Treatment. International Journal of Molecular Sciences, 22, Article No. 6716. https://doi.org/10.3390/ijms22136716
|
[20]
|
Nomura, H., Mukai, M., Niimi, Y., et al. (2017) Coexistence of Ac-quired Perforating Dermatosis and Bullous Pemphigoid: Three Cases. European Journal of Dermatology, 27, 192-193. https://doi.org/10.1684/ejd.2016.2944
|
[21]
|
Oliveira, M.C.B., de Brito, M.H. and Simabukuro, M.M. (2020) Cen-tral Nervous System Demyelination Associated with Immune Checkpoint Inhibitors: Review of the Literature. Frontiers in Neurology, 11, Article ID: 538695.
https://doi.org/10.3389/fneur.2020.538695
|
[22]
|
Bjoern, J., Juul Nitschke, N., Zeeberg, I.T., et al. (2016) Immuno-logical Correlates of Treatment and Response in Stage IV Malignant Melanoma Patients Treated with Ipilimumab. On-coimmunology, 5, e1100788.
https://doi.org/10.1080/2162402X.2015.1100788
|
[23]
|
Li, Y., Zhang, X. and Zhao, C. (2021) Guillain-Barre Syn-drome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases. BioMed Research International, 2021, Article ID: 9800488.
https://doi.org/10.1155/2021/9800488
|
[24]
|
Garcia, C.A., El-Ali, A., Rath, T.J., et al. (2018) Neurologic Im-mune-Related Adverse Events Associated with Adjuvant Ipilimumab: Report of Two Cases. Journal for ImmunoThera-py of Cancer, 6, Article No. 83.
https://doi.org/10.1186/s40425-018-0393-z
|
[25]
|
Thompson, J.A., Schneider, B.J., Brahmer, J., et al. (2020) NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. Journal of the National Comprehensive Cancer Network, 18, 230-241.
https://doi.org/10.6004/jnccn.2020.0012
|
[26]
|
Haugh, A.M., Probasco, J.C. and Johnson, D.B. (2020) Neurologic Complications of Immune Checkpoint Inhibitors. Expert Opinion on Drug Safety, 19, 479-488. https://doi.org/10.1080/14740338.2020.1738382
|
[27]
|
Safa, H., Johnson, D.H., Trinh, V.A., et al. (2019) Immune Checkpoint Inhibitor Related Myasthenia Gravis: Single Center Experience and Systematic Review of the Literature. Journal for ImmunoTherapy of Cancer, 7, Article No. 319.
https://doi.org/10.1186/s40425-019-0774-y
|
[28]
|
Xu, M., Nie, Y., Yang, Y., et al. (2019) Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors: A Systematic Re-view and Meta-Analysis. Neurologist, 24, 75-83.
https://doi.org/10.1097/NRL.0000000000000230
|
[29]
|
Johnson, D.B., Manouchehri, A., Haugh, A.M., et al. (2019) Neurologic Toxicity Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study. Journal for Immuno-Therapy of Cancer, 7, Article No. 134.
https://doi.org/10.1186/s40425-019-0617-x
|
[30]
|
Howard, F.M., Lennon, V.A., Finley, J., et al. (1987) Clinical Correlations of Antibodies That Bind, Block, or Modulate Human Acetylcholine Receptors in Myasthenia Gravis. Annals of the New York Academy of Sciences, 505, 526-538.
https://doi.org/10.1111/j.1749-6632.1987.tb51321.x
|
[31]
|
Meriggioli, M.N. and Sanders, D.B. (2012) Muscle Au-toantibodies in Myasthenia Gravis: Beyond Diagnosis? Expert Review of Clinical Immunology, 8, 427-438. https://doi.org/10.1586/eci.12.34
|
[32]
|
Huang, Y.T., Chen, Y.P., Lin, W.C., et al. (2020) Immune Checkpoint In-hibitor-Induced Myasthenia Gravis. Frontiers in Neurology, 11, Article No. 634. https://doi.org/10.3389/fneur.2020.00634
|
[33]
|
Kao, J.C., Liao, B., Markovic, S.N., et al. (2017) Neurological Complications Associated with Anti-Programmed Death 1 (PD-1) Antibodies. JAMA Neurology, 74, 1216-1222. https://doi.org/10.1001/jamaneurol.2017.1912
|
[34]
|
Moreira, A., Loquai, C., Pfohler, C., et al. (2019) Myositis and Neuromuscular Side-Effects Induced by Immune Checkpoint Inhibitors. European Journal of Cancer, 106, 12-23. https://doi.org/10.1016/j.ejca.2018.09.033
|
[35]
|
Touat, M., Maisonobe, T., Knauss, S., et al. (2018) Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer. Neurology, 91, e985-e994. https://doi.org/10.1212/WNL.0000000000006124
|
[36]
|
Pinto, D., Gouveia, P., Sousa, B., et al. (2016) Reply to the Letter to the Editor “Insertion of Central Venous Catheters (CVCs): Any Changes in the Past Ten Years” by Biffi et al. Annals of Oncology, 27, 1351-1352.
https://doi.org/10.1093/annonc/mdw149
|
[37]
|
Haddox, C.L., Shenoy, N., Shah, K.K., et al. (2017) Pembrolizumab Induced Bulbar Myopathy and Respiratory Failure with Necrotizing Myositis of the Diaphragm. Annals of Oncology, 28, 673-675.
https://doi.org/10.1093/annonc/mdw655
|
[38]
|
Khoo, A., Zhuang, Y., Boundy, K., et al. (2019) Immune Checkpoint Inhibitor-Related Myositis Associated with Atezolizumab Therapy. Neurology Clinical Practice, 9, e25-e26. https://doi.org/10.1212/CPJ.0000000000000597
|